Glioblastoma Multiforme Therapy and Mechanisms of Resistance

@inproceedings{Ramirez2013GlioblastomaMT,
  title={Glioblastoma Multiforme Therapy and Mechanisms of Resistance},
  author={Yulian P. Ramirez and Jessica Leigh Weatherbee and Richard T Wheelhouse and Alonzo H. Ross},
  booktitle={Pharmaceuticals},
  year={2013}
}
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 141 references

Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme

Journal of Cancer Research and Clinical Oncology • 2004
View 9 Excerpts
Highly Influenced

Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

Molecular therapy : the journal of the American Society of Gene Therapy • 2013
View 8 Excerpts
Highly Influenced

Temozolomide: mechanisms of action, repair and resistance.

Current molecular pharmacology • 2012
View 8 Excerpts
Highly Influenced

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2007
View 9 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…